Effect of B-GOS on GI Discomfort in Healthy Adults

November 26, 2013 updated by: Clasado Limited

Double-blind, Placebo Controlled, Randomised, Multicentered, of Parallel Design Study to Determine the Effect of B-GOS on GI Discomfort in Healthy Adults

The aim of the study is to evaluate the effects of a new food supplement which is currently available in the market, called Bimuno® (B-GOS), on gastrointestinal discomfort (e.g. bloating, abdominal pain/cramp and flatulence) in adults who often experience these symptoms but are otherwise healthy.

About 400 volunteers will take part in this study, which will last 6 weeks (to include 4 weeks treatment and 2 weeks follow up period).

Episodes of abdominal pain or discomfort (e.g. bloating, abdominal pain/cramp and flatulence), in the absence of diseases, are commonly associated with food or drug intake or with alterations of bowel habit and vary between individuals in frequency and severity.

Some dietary ingredients are known to reduce these symptoms. We have used B-GOS previously in trials with healthy younger and older adults and we have observed a trend towards reducing abdominal bloating. However, the investigators have not tested B-GOS in healthy adults who often experience these symptoms and this is what we will investigate now.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

400

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oxford, United Kingdom, OX11 9LH
        • Research Insights Ltd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged between 18 and 65 years old.
  2. Presence of bloated feeling or experiencing abdominal fullness, with or without visible distention, often in the last 12 months.
  3. Ability to communicate well with the investigator and to comply with the requirements of the entire study.
  4. Volunteer has given written informed consent to participate and is willing to participate in the entire study.

Exclusion Criteria:

  1. History or evidence of organic disease of the gastrointestinal tract; such as tumour, irritable bowel syndrome, etc., within the previous 5 years.
  2. Undergone surgical resection of any part of the bowel.
  3. History of malignancy within the previous 5 years (with exception of well-treated basal cell carcinoma or in situ cervical carcinoma).
  4. Received antibiotics in the previous four weeks.
  5. Consumed probiotic or prebiotic preparations on a regular basis (at least 3 times per week) in the last 2 weeks.
  6. Former participation in another study involving prebiotic or probiotic preparations or investigational drugs within the previous one month, or intention to use such drugs during the course of the study.
  7. Severe allergy or any history of severe abnormal drug reaction, drug or alcohol abuse.
  8. Regular use of any medication with exception of hormonal replacement therapy and contraception.
  9. Women who are pregnant or breast-feeding.
  10. Fertile women not practicing a medically-approved method of contraception.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: B-GOS
2.75g daily for 4 weeks
Other Names:
  • Bimuno
Placebo Comparator: Maltodextrin
2.75g daily for 4 weeks
Other Names:
  • corn syrup

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine the effect of B-GOS on GI discomfort
Time Frame: Participants will be followed daily for 6 weeks
questionnaires
Participants will be followed daily for 6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To conduct an assessment of stools
Time Frame: Participants will be followed daily for 6 weeks.
questionnaires
Participants will be followed daily for 6 weeks.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the effect of B-GOS on the quality of life and general well being.
Time Frame: beginning and end of the study
questionnaires
beginning and end of the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Actual)

November 1, 2013

Study Completion (Actual)

November 1, 2013

Study Registration Dates

First Submitted

February 25, 2013

First Submitted That Met QC Criteria

April 2, 2013

First Posted (Estimate)

April 5, 2013

Study Record Updates

Last Update Posted (Estimate)

November 27, 2013

Last Update Submitted That Met QC Criteria

November 26, 2013

Last Verified

April 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • CLAS/1213

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Maltodextrin

3
Subscribe